BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....
BioCentury | Jul 27, 2018
Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

...The company hopes to start a Phase III trial of the dual mucoactive-antibacterial in 1H19. NovaBiotics...
...of CARE CF 1 were safety and the change from baseline in sputum bacterial load. NovaBiotics...
...plus SOC led to numeric reductions in sputum neutrophil elastase and C-reactive protein (CRP) levels. NovaBiotics Ltd....
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...the endogenous human protein kininogen, which is in Phase II for acute external otitis. And NovaBiotics Ltd....
...NASDAQ:DPRX), New York, N.Y. National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd....
BioCentury | Jan 26, 2015
Financial News

NovaBiotics completes venture financing

NovaBiotics Ltd. , Aberdeen, U.K. Business: Infectious, Supply/Service Date completed: 2015-01-20 Type: Venture financing Raised: £5 million ($7.6 million) Investor: Woodford Investment Management WIR Staff Infectious...
BioCentury | Sep 29, 2014
Clinical News

Cysteamine: Phase IIa started

...CF. The product has Orphan Drug designation in the U.S. and EU to treat CF. NovaBiotics Ltd....
BioCentury | Sep 29, 2014
Clinical News

Oral Lynovex cysteamine regulatory update

...FDA granted Orphan Drug designation to NovaBiotics' Lynovex cysteamine to treat cystic fibrosis. NovaBiotics is developing...
...are expected to start in 2H15. Lynovex also has Orphan Drug designation in the EU. NovaBiotics Ltd....
BioCentury | Dec 23, 2013
Clinical News

Lynovex cysteamine: Phase IIa start

...Next quarter, NovaBiotics will begin a U.K. Phase IIa trial to evaluate a tablet formulation of...
...partly fund the trial. Lynovex has Orphan Drug designation in the EU to treat CF. NovaBiotics Ltd....
BioCentury | Sep 2, 2013
Company News

NovaBiotics, Taro deal

...Taro received an exclusive license to Novexatin . Taro and NovaBiotics' will co-develop the topical cyclic...
...treat onychomycosis along with other undisclosed development. The partners could not be reached for details. NovaBiotics Ltd....
BioCentury | Jan 2, 2012
Clinical News

Lynovex cysteamine regulatory update

...The European Commission granted Orphan Drug designation for NovaBiotics' Lynovex cysteamine to treat cystic fibrosis (CF...
...treat cystic fibrosis (CF). The dual mucoactive antibacterial is in preclinical testing for the indication. NovaBiotics Ltd....
Items per page:
1 - 10 of 14
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....
BioCentury | Jul 27, 2018
Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

...The company hopes to start a Phase III trial of the dual mucoactive-antibacterial in 1H19. NovaBiotics...
...of CARE CF 1 were safety and the change from baseline in sputum bacterial load. NovaBiotics...
...plus SOC led to numeric reductions in sputum neutrophil elastase and C-reactive protein (CRP) levels. NovaBiotics Ltd....
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...the endogenous human protein kininogen, which is in Phase II for acute external otitis. And NovaBiotics Ltd....
...NASDAQ:DPRX), New York, N.Y. National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd....
BioCentury | Jan 26, 2015
Financial News

NovaBiotics completes venture financing

NovaBiotics Ltd. , Aberdeen, U.K. Business: Infectious, Supply/Service Date completed: 2015-01-20 Type: Venture financing Raised: £5 million ($7.6 million) Investor: Woodford Investment Management WIR Staff Infectious...
BioCentury | Sep 29, 2014
Clinical News

Cysteamine: Phase IIa started

...CF. The product has Orphan Drug designation in the U.S. and EU to treat CF. NovaBiotics Ltd....
BioCentury | Sep 29, 2014
Clinical News

Oral Lynovex cysteamine regulatory update

...FDA granted Orphan Drug designation to NovaBiotics' Lynovex cysteamine to treat cystic fibrosis. NovaBiotics is developing...
...are expected to start in 2H15. Lynovex also has Orphan Drug designation in the EU. NovaBiotics Ltd....
BioCentury | Dec 23, 2013
Clinical News

Lynovex cysteamine: Phase IIa start

...Next quarter, NovaBiotics will begin a U.K. Phase IIa trial to evaluate a tablet formulation of...
...partly fund the trial. Lynovex has Orphan Drug designation in the EU to treat CF. NovaBiotics Ltd....
BioCentury | Sep 2, 2013
Company News

NovaBiotics, Taro deal

...Taro received an exclusive license to Novexatin . Taro and NovaBiotics' will co-develop the topical cyclic...
...treat onychomycosis along with other undisclosed development. The partners could not be reached for details. NovaBiotics Ltd....
BioCentury | Jan 2, 2012
Clinical News

Lynovex cysteamine regulatory update

...The European Commission granted Orphan Drug designation for NovaBiotics' Lynovex cysteamine to treat cystic fibrosis (CF...
...treat cystic fibrosis (CF). The dual mucoactive antibacterial is in preclinical testing for the indication. NovaBiotics Ltd....
Items per page:
1 - 10 of 14